Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Noviello, D; Chaparro, M; Viganò, C; Blesl, A; Barberio, B; Yanai, H; Orlando, A; Ferreiro-Iglesias, R; Bezzio, C; Zilli, A; Molnár, T; Gheorghe, C; Conforti, F; Innocenti, T; Saibeni, S; Bossuyt, P; Oliveira, R; Carvalhas, Gabrielli, AM; Losco, A; Vieujean, S; Tettoni, E; Pirola, L; Calderone, S; Kornowski, Cohen, M; Dragoni, G; Rath, T; Barreiro-de, Acosta, M; Savarino, EV; Gisbert, JP; Vecchi, M; Atreya, R; Caprioli, F.
Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study.
J Crohns Colitis. 2025; 19(5): Doi: 10.1093/ecco-jcc/jjaf056 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Co-Autor*innen der Med Uni Graz
Blesl Andreas
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
BACKGROUND AND AIMS: Inflammatory bowel disease (IBD) patients with Clostridioides difficile infection (CDI) are at increased risk of adverse outcomes. Data on fidaxomicin use in IBD remain scarce. We assessed the effectiveness and safety of fidaxomicin for CDI and its impact on IBD outcomes in a large international cohort. METHODS: Adult patients with ulcerative colitis (UC) or Crohn's disease (CD) treated with fidaxomicin for documented CDI were retrospectively included. The primary outcome was CDI recurrence rate within 8 weeks (C. difficile toxin detection and CDI-targeted therapy). Secondary outcomes included sustained response (no CDI-targeted therapy within 12 weeks), IBD therapy escalation, colectomy rate, and all-cause mortality within 30, 90, and 180 days. RESULTS: Ninety-six patients (57 UC and 39 CD) from 20 IBD centers were included. Most were on advanced IBD therapy. Half had a previous CDI episode, 15% a severe episode. CDI recurrence rate was 10% at week 8, and sustained response 82% at week 12. Compared with patients with previous CDI episode, patients at first episode tended to have a lower recurrence (4.3% vs 16%; P = .06) and higher sustained response (91% vs 75%; P = .04) rate. IBD therapy escalation was required in 48% with a numerically lower need for patients achieving vs not-achieving sustained response within 30 days (12% vs 20%; P = .42). Five UC patients underwent colectomy. One death unrelated to CDI or IBD occurred. One moderate and 5 mild adverse events were reported. CONCLUSIONS: Fidaxomicin was effective and safe in IBD patients with CDI, with greater effectiveness in CDI-naïve patients, potentially influencing short-term IBD outcomes.
Find related publications in this database (using NLM MeSH Indexing)
Adult - administration & dosage
Aged - administration & dosage
Female - administration & dosage
Humans - administration & dosage
Male - administration & dosage
Middle Aged - administration & dosage
Anti-Bacterial Agents - therapeutic use, adverse effects
Clostridioides difficile - isolation & purification
Clostridium Infections - complications, diagnosis, drug therapy, microbiology
Colectomy - statistics & numerical data
Colitis, Ulcerative - complications
Crohn Disease - complications
Fidaxomicin - therapeutic use, adverse effects
Recurrence - administration & dosage
Retrospective Studies - administration & dosage
Treatment Outcome - administration & dosage

Find related publications in this database (Keywords)
fidaxomicin
Clostridioides difficile
CDI
inflammatory bowel disease
© Med Uni Graz • Impressum